SUPERNUS PHARMACEUTICALS INC (SUPN)
US8684591089 - Common Stock
Overall SUPN gets a fundamental rating of 6 out of 10. We evaluated SUPN against 193 industry peers in the Pharmaceuticals industry. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on SUPN. These ratings could make SUPN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
SUPN had a positive operating cash flow in the past year.
In the past 5 years SUPN has always been profitable.
SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
SUPN has a better Return On Assets (4.45%) than 86.91% of its industry peers.
Looking at the Return On Equity, with a value of 5.93%, SUPN belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
SUPN has a better Return On Invested Capital (5.97%) than 82.72% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 43.18%.
The last Return On Invested Capital (5.97%) for SUPN is above the 3 year average (3.33%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.45% | ||
| ROE | 5.93% | ||
| ROIC | 5.97% |
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
1.3 Margins
With an excellent Profit Margin value of 9.16%, SUPN belongs to the best of the industry, outperforming 86.39% of the companies in the same industry.
SUPN's Profit Margin has declined in the last couple of years.
SUPN has a Operating Margin of 12.19%. This is amongst the best in the industry. SUPN outperforms 84.29% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
SUPN has a better Gross Margin (89.04%) than 92.15% of its industry peers.
SUPN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.19% | ||
| PM (TTM) | 9.16% | ||
| GM | 89.04% |
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
2. Health
2.1 Basic Checks
SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SUPN has more shares outstanding
SUPN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 5.05 indicates that SUPN is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.05, SUPN is doing good in the industry, outperforming 79.58% of the companies in the same industry.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.05 |
ROIC/WACC0.64
WACC9.37%
2.3 Liquidity
SUPN has a Current Ratio of 2.20. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.20, SUPN is in line with its industry, outperforming 42.93% of the companies in the same industry.
SUPN has a Quick Ratio of 1.98. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN has a Quick ratio of 1.98. This is comparable to the rest of the industry: SUPN outperforms 45.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.98 |
3. Growth
3.1 Past
SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 134.04%, which is quite impressive.
SUPN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.43% yearly.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 6.78%.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.24% yearly.
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS Q2Q%187.5%
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Sales Q2Q%14.17%
3.2 Future
SUPN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.16% yearly.
The Revenue is expected to grow by 7.08% on average over the next years.
EPS Next Y108.13%
EPS Next 2Y17.45%
EPS Next 3Y19.35%
EPS Next 5Y24.16%
Revenue Next Year7.34%
Revenue Next 2Y1.87%
Revenue Next 3Y4.15%
Revenue Next 5Y7.09%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.10, SUPN is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 85.86% of the companies listed in the same industry.
SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
SUPN is valuated rather expensively with a Price/Forward Earnings ratio of 18.35.
Based on the Price/Forward Earnings ratio, SUPN is valued cheaper than 80.63% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SUPN to the average of the S&P500 Index (23.73), we can say SUPN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.1 | ||
| Fwd PE | 18.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaply inside the industry as 92.15% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaper than 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.37 | ||
| EV/EBITDA | 7.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SUPN has a very decent profitability rating, which may justify a higher PE ratio.
SUPN's earnings are expected to grow with 19.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y17.45%
EPS Next 3Y19.35%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUPERNUS PHARMACEUTICALS INC
NASDAQ:SUPN (12/20/2024, 8:00:00 PM)
After market: 35.43 0 (0%)35.43
-0.34 (-0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners110.07%
Inst Owner Change2.19%
Ins Owners3.91%
Ins Owner Change0.15%
Market Cap1.96B
Analysts80
Price Target40.03 (12.98%)
Short Float %12.31%
Short Ratio18.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.54%
Min EPS beat(2)-9.5%
Max EPS beat(2)52.59%
EPS beat(4)2
Avg EPS beat(4)17.11%
Min EPS beat(4)-32.33%
Max EPS beat(4)57.69%
EPS beat(8)4
Avg EPS beat(8)20.2%
EPS beat(12)5
Avg EPS beat(12)0.79%
EPS beat(16)8
Avg EPS beat(16)9%
Revenue beat(2)2
Avg Revenue beat(2)10.18%
Min Revenue beat(2)9.5%
Max Revenue beat(2)10.86%
Revenue beat(4)3
Avg Revenue beat(4)5.21%
Min Revenue beat(4)-3.43%
Max Revenue beat(4)10.86%
Revenue beat(8)5
Avg Revenue beat(8)2.24%
Revenue beat(12)8
Avg Revenue beat(12)1.82%
Revenue beat(16)10
Avg Revenue beat(16)1.41%
PT rev (1m)0%
PT rev (3m)-3.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.91%
EPS NY rev (1m)9.45%
EPS NY rev (3m)41.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.1 | ||
| Fwd PE | 18.35 | ||
| P/S | 3 | ||
| P/FCF | 11.37 | ||
| P/OCF | 11.34 | ||
| P/B | 1.94 | ||
| P/tB | 5.59 | ||
| EV/EBITDA | 7.26 |
EPS(TTM)2.2
EY6.21%
EPS(NY)1.93
Fwd EY5.45%
FCF(TTM)3.12
FCFY8.79%
OCF(TTM)3.12
OCFY8.82%
SpS11.81
BVpS18.24
TBVpS6.34
PEG (NY)0.15
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.45% | ||
| ROE | 5.93% | ||
| ROCE | 7.56% | ||
| ROIC | 5.97% | ||
| ROICexc | 9.69% | ||
| ROICexgc | N/A | ||
| OM | 12.19% | ||
| PM (TTM) | 9.16% | ||
| GM | 89.04% | ||
| FCFM | 26.39% |
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
ROICexc(3y)4.56%
ROICexc(5y)9.78%
ROICexgc(3y)55.58%
ROICexgc(5y)44.39%
ROCE(3y)4.65%
ROCE(5y)8.65%
ROICexcg growth 3Y27.21%
ROICexcg growth 5Y23.08%
ROICexc growth 3Y-54.6%
ROICexc growth 5Y-42.12%
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.56% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | 1727.26 | ||
| Cash Conversion | 106.05% | ||
| Profit Quality | 288.16% | ||
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.98 | ||
| Altman-Z | 5.05 |
F-Score8
WACC9.37%
ROIC/WACC0.64
Cap/Depr(3y)2.42%
Cap/Depr(5y)13.27%
Cap/Sales(3y)0.17%
Cap/Sales(5y)0.37%
Profit Quality(3y)2941.76%
Profit Quality(5y)1811.14%
High Growth Momentum
Growth
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS Q2Q%187.5%
EPS Next Y108.13%
EPS Next 2Y17.45%
EPS Next 3Y19.35%
EPS Next 5Y24.16%
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Sales Q2Q%14.17%
Revenue Next Year7.34%
Revenue Next 2Y1.87%
Revenue Next 3Y4.15%
Revenue Next 5Y7.09%
EBIT growth 1Y164.85%
EBIT growth 3Y-56.57%
EBIT growth 5Y-36.49%
EBIT Next Year16.63%
EBIT Next 3Y12.89%
EBIT Next 5Y16.38%
FCF growth 1Y25.05%
FCF growth 3Y-6.45%
FCF growth 5Y-2.92%
OCF growth 1Y25.02%
OCF growth 3Y-7.07%
OCF growth 5Y-2.95%